--- Dr. Ran Reshef (the Clinical Lead for the CAR-T Cell Program at Columbia)
Chimeric antigen receptor (CAR) T-cell therapy represents an immunotherapeutic approach that enhances the immune system's ability to detect and eliminate cancer cells. The intricate nature of the human immune system encompasses diverse cell populations and intricate signaling networks distributed throughout the body. Within this context, lymphocytes, a subset of white blood cells, play a crucial role in combating infections. Specifically, T cells, a type of lymphocyte, exhibit the capacity to recognize and eliminate cancer cells as well as virally infected cells. Harnessing the potential of T cells in CAR T-cell therapy, researchers aim to bolster their tumor-targeting capabilities. By doing so, CAR T-cell therapy holds promise in enabling T cells to overcome the evasive mechanisms employed by cancer cells, facilitating their selective destruction.
CAR T-cell therapy has emerged as a viable treatment option for various malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL) in the pediatric and young adult population up to the age of 25. Notably, the U.S. Food and Drug Administration (FDA) has granted approval to five CAR T-cell therapies as of March 2021.
The landscape of CAR T-cell therapy research extends beyond its current applications, encompassing investigations into the utilization of existing FDA-approved products for novel indications and in populations with limited treatment options. Concurrently, efforts are underway to enhance the safety profile of CAR T-cell therapy, thereby mitigating potential adverse events associated with its administration. The ongoing advancements in CAR T-cell therapy research evoke a sense of optimism within the cancer community, fostering anticipation for its future prospects and the transformative impact it holds for individuals affected by cancer.
Cyagen based on its years of research experience in the field of tumor immunotherapy can provide CAR-T and other cell therapy researchers with services and comprehensive support for the research and development of CAR-T and other cell therapies.
This session is ideal for researchers, scientists, and medical professionals interested in the latest developments in cell therapy, and particularly the application of CAR-T cell therapy in cancer treatment. Dive into this groundbreaking field with us, as we lead the path into the new era of cancer treatment.
